Catalog No.

KHC09602

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for Human ERBB2 has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Human ERBB2 present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-labeled antibody specific for Human ERBB2 is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Human ERBB2 bound in the initial step. The color development is stopped and the intensity of the color is measured.

Specificity

Human ERBB2

Applications

Used for the quantitative determination of Human ERBB2 concentration in serum, plasma and cell culture supernatant.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.78 - 50 ng/mL

Sensitivity

0.13 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	25.4	6.8	1.6	25.5	6.7	1.6
Standard deviation	0.5	0.2	0.1	1.4	0.3	0.1
CV (%)	2.1	3.2	7.3	5.4	4.0	7.0

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study., PMID:40514709

Dynamics of mitochondrial DNA copy number regulation in relation to gastric cancer survival., PMID:40514632

A tunable gene therapy for heart regeneration., PMID:40514437

Di (2-ethylhexyl) Phthalate decrease pregnancy rate via disrupting the microbe-gut-hypothalamic-pituitary-ovarian axis in mice., PMID:40514374

Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type., PMID:40512776

Genomic Signatures of Gastric Adenocarcinoma By Tumor Location-Modified Laurén Classification: Highlighting the Molecular Heterogeneity of Mixed-Type Tumors., PMID:40512601

ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial., PMID:40512191

Knockdown of Claudin-8 (CLDN8) Indicates a Link Between Breast Cancer Cell Sensitivity to Chemotherapeutics and Reveals a Potential Use of CLDN8 as a Molecular Diagnostic and Target for Therapy., PMID:40508219

Sex Hormones and Iron-Related Biomarkers Associate with EMT Features and Tumor Stage in Colorectal Cancer: A Serum- and Tissue-Based Analysis., PMID:40507970

Mutational Patterns in Colorectal Cancer: Do PDX Models Retain the Heterogeneity of the Original Tumor?, PMID:40507920

Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement., PMID:40507325

Clinical Application of Next-Generation Sequencing for Molecular Classification in the Management of Endometrial Cancer: An Observational Cohort Study., PMID:40507285

Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature., PMID:40506517

Hereditary breast cancer beyond BRCA: clinicopathological characteristics and long-term outcomes., PMID:40504267

RNF213-Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells., PMID:40503863

Analytical validation of Aspyre Clinical Test for Lung (Blood): A multiplexed PCR and pyrophosphorolysis-based assay for detecting actionable NSCLC variants in plasma cfDNA and cfRNA., PMID:40503460

Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience., PMID:40503459

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma., PMID:40502048

Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study., PMID:40500959

ERBB2-Low Expression by Race and Ethnicity Among Patients With Triple-Negative Breast Cancer., PMID:40498483

Noninvasive markers for warning premature ovarian insufficiency: a Mendelian randomisation study., PMID:40495196

Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation., PMID:40494858

Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer., PMID:40489875

Mechanisms Underlying the Therapeutic Effects of Brucea javanica in Cervical Cancer Treatment Based on Network Pharmacology and Molecular Docking., PMID:40487864

Improved Sampling Method to Enhance the Positive Rate of HER2 Detection in Gastric Cancer., PMID:40485523

Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype., PMID:40482645

Axillary staging with 18F-FDG PET/CT in early breast cancer: impact of tumor subtypes., PMID:40482189

A homogeneous mass-encoded strategy for mass spectrometric biosensing of multiplex proteins., PMID:40480694

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers., PMID:40480221

NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition., PMID:40473905

Are ERBB2 RNA-High, Amplification-Negative Tumors a Missed Opportunity for Targeted Therapy?, PMID:40472940

Is the Molecular Classification of ERBB2 in Stage III Colon Cancer Clinically Ready?, PMID:40472938

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040

Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report., PMID:40470107

Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report., PMID:40469473

Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors., PMID:40469307

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744

Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials., PMID:40468250

Novel receptor tyrosine kinase-targeted strategies to overcome resistance in oral squamous cell carcinoma., PMID:40468099

Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer., PMID:40467708

Genome-wide DNA methylation analysis of hippocampal tissue in a murine model of attention deficit-hyperactivity disorder., PMID:40465750

STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models., PMID:40465424

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer., PMID:40464376

CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study., PMID:40461325

Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510

Assessing the Relationship among Tumor Size, Lymph Node Status, and ER/PR/HER2 Expression in Patients with Breast Cancer., PMID:40460385

Patritumab deruxtecan induces immunogenic cell death., PMID:40458967

T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer., PMID:40455140

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update., PMID:40451403

Document Download

Human ERBB2 ELISA Kit.pdf